Immunosuppressive therapy improves both short- and long-term prognosis in patients with virus-negative nonfulminant inflammatory cardiomyopathy

Circulation: Heart Failure

Volumn 11, Issue 2, 2018, Pages

  Merken, Jort ^a   Hazebroek, Mark ^a   Van Paassen, Pieter ^a   Verdonschot, Job ^a   Van Empel, Vanessa ^a   Knackstedt, Christian ^a   Abdul Hamid, Myrurgia ^a   Seiler, Michael ^b   Kolb, Julian ^b   Hoermann, Philipp ^b   Ensinger, Christian ^b   Brunner La Rocca, Hans Peter ^a   Poelzl, Gerhard ^b   Heymans, Stephane ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Heart failure; Immunosuppression; Inflammatory cardiomyopathy; Prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; LOSARTAN; METOPROLOL; MINERALOCORTICOID ANTAGONIST; MYCOPHENOLIC ACID; PERINDOPRIL; PREDNISONE; SPIRONOLACTONE; STEROID;

ADULT; ANEMIA; ARTICLE; CARDIOMYOPATHY; CLINICAL OUTCOME; DIABETES MELLITUS; FEMALE; FEMUR HEAD NECROSIS; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MIDDLE AGED; PRACTICE GUIDELINE; PROGNOSIS; PROPENSITY SCORE; RETROSPECTIVE STUDY; SURVIVAL; AGED; HEART STROKE VOLUME; HEART TRANSPLANTATION; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS;

ADULT; AGED; CARDIOMYOPATHIES; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; STROKE VOLUME; VIRUSES;

EID: 85052327876     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.117.004228     Document Type: Article

References (29)

1. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T, Lindinger A, Böhm M. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118:639–648. doi: 10.1161/CIRCULATIONAHA.108.769489.
2. Parrillo JE, Cunnion RE, Epstein SE, Parker MM, Suffredini AF, Brenner M, Schaer GL, Palmeri ST, Cannon RO 3rd, Alling D, Wittes JT, Ferrans VJ, Rodriguez ER, Fauci AS. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med. 1989;321:1061–1068.
3. Latham RD, Mulrow JP, Virmani R, Robinowitz M, Moody JM. Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. Am Heart J. 1989;117:876–882.
4. Jones SR, Herskowitz A, Hutchins GM, Baughman KL. Effects of immunosuppressive therapy in biopsy-proved myocarditis and borderline myocarditis on left ventricular function. Am J Cardiol. 1991;68:370–376.
5. Maisch B, Schönian U, Hengstenberg C, Herzum M, Hufnagel G, Bethge C, Bittinger A, Neumann K. Immunosuppressive treatment in autoreactive myocarditis–results from a controlled trial. Postgrad Med J. 1994;70(suppl 1):S29–S34.
6. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wil-czewski P, Niklewski T, Zembala M, Polonski L, Rozek MM, Wodniecki J. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104:39–45.
7. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003;107:857–863.
8. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009;30:1995–2002. doi: 10.1093/eurheartj/ehp249.
9. Mason JW, O’Connell JB, Herskowitz A, Rose NR, McManus BM, Bill-ingham ME, Moon TE. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333:269–275. doi: 10.1056/NEJM199508033330501.
10. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Heliö T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McK-enna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636–2648, 2648a–2648d. doi: 10.1093/eurheartj/ eht210.
11. Escher F, Kühl U, Lassner D, Poller W, Westermann D, Pieske B, Tschöpe C, Schultheiss HP. Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. Clin Res Cardiol. 2016;105:1011–1020. doi: 10.1007/s00392-016-1011-z.
12. Hazebroek MR, Moors S, Dennert R, van den Wijngaard A, Krapels I, Hoos M, Verdonschot J, Merken JJ, de Vries B, Wolffs PF, Crijns HJ, Brunner-La Rocca HP, Heymans S. Prognostic relevance of gene-environment interactions in patients with dilated cardiomyopathy: applying the MOGE(S) classification. J Am Coll Cardiol. 2015;66:1313–1323. doi: 10.1016/j. jacc.2015.07.023.
13. Maisch B, Ruppert V, Pankuweit S. Management of fulminant myocarditis: a diagnosis in search of its etiology but with therapeutic options. Curr Heart Fail Rep. 2014;11:166–177. doi: 10.1007/s11897-014-0196-6.
14. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, Morehead A, Kitzman D, Oh J, Quinones M, Schiller NB, Stein JH, Weiss-man NJ; American Society of Echocardiography. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr. 2004;17:1086–1119. doi: 10.1016/j. echo.2004.07.013.
15. Dennert R, Velthuis S, Schalla S, Eurlings L, van Suylen RJ, van Paassen P, Tervaert JW, Wolffs P, Goossens VJ, Bruggeman C, Waltenberger J, Crijns HJ, Heymans S. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antivir Ther. 2010;15:193–201. doi: 10.3851/IMP1516.
16. Hazebroek MR, Kemna MJ, Schalla S, Sanders-van Wijk S, Gerretsen SC, Dennert R, Merken J, Kuznetsova T, Staessen JA, Brunner-La Rocca HP, van Paassen P, Cohen Tervaert JW, Heymans S. Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. Int J Cardiol. 2015;199:170–179. doi: 10.1016/j.ijcard.2015.06.087.
17. Badorff C, Schwimmbeck PL, Kühl U, Gerhold M, Stein H, Schultheiss HP. [Cardiac sarcoidosis: diagnostic validation by endomyocardial biopsy and therapy with corticosteroids]. Z Kardiol. 1997;86:9–14.
18. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis–natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med. 1997;336:1860–1866. doi: 10.1056/ NEJM199706263362603.
19. Cooper LT Jr, ElAmm C. Giant cell myocarditis. Diagnosis and treatment. Herz. 2012;37:632–636. doi: 10.1007/s00059-012-3658-1.
20. McCarthy RE III, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, Baughman KL. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med. 2000;342:690–695. doi: 10.1056/NEJM200003093421003.
21. Rose NR. Viral damage or ‘molecular mimicry’-placing the blame in myocarditis. Nat Med. 2000;6:631–632. doi: 10.1038/76199.
22. Kaya Z, Leib C, Katus HA. Autoantibodies in heart failure and cardiac dysfunction. Circ Res. 2012;110:145–158. doi: 10.1161/CIRCRESAHA.111.243360.
23. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995;333:958–963. doi: 10.1056/NEJM199510123331502.
24. Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, Mau-rier F, Decaux O, Ninet J, Gobert P, Quémeneur T, Blanchard-Delaunay C, Godmer P, Puéchal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L; French Vasculitis Study Group. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771–1780. doi: 10.1056/NEJMoa1404231.
25. Kaufmann BA, Goetschalckx K, Min SY, Maeder MT, Bucher U, Nietlispach F, Bernheim AM, Pfisterer ME, Brunner-La Rocca HP; TIME-CHF Investigators. Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy. Int J Cardiol. 2015;191:286–293. doi: 10.1016/j.ijcard.2015.04.282.
26. Ohtsuka T, Hamada M, Hiasa G, Sasaki O, Suzuki M, Hara Y, Shigematsu Y, Hiwada K. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;37:412–417.
27. Neri Serneri GG, Boddi M, Modesti PA, Coppo M, Cecioni I, Toscano T, Papa ML, Bandinelli M, Lisi GF, Chiavarelli M. Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Circ Res. 2004;94:1630–1637. doi: 10.1161/01.RES.0000130944.49657.b8.
28. Manabe S, Okura T, Watanabe S, Fukuoka T, Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol. 2005;46:735–739.
29. Ridker PM, Danielson E, Rifai N, Glynn RJ; Val-MARC Investigators. Val-sartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006;48:73–79. doi: 10.1161/01. HYP.0000226046.58883.32.